IDH1 and central nervous system cancer: The significantly younger age at glioma diagnosis of ATM GV carriers may at least partly be explained by the younger median age of patients presenting with IDH-mutant astrocytoma (38 years) [9], compared with a peak incidence of IDH-wildtype glioblastoma between 55 and 85 years [44].